Arcadia Biosciences Q2 Loss Widens to $6.3M, but Zola Sales Inflect with July Revenue Topping $740K
RKDA is trading near its 52-week low of $0.497 (15% above the low) on light trading volume (0.2× avg).
Summary
Arcadia Biosciences reported a wider Q2 net loss of $6.27 million, but highlighted a sharp inflection in Zola sales with July revenue exceeding $740,000 and new product launches planned for Q4 2026 and H1 2027.
Key Events · Earnings and Guidance · RKDA
-
Q2 Net Loss Widens to $6.27M
Net loss attributable to common stockholders was $6.27 million, or $2.09 per share, compared to $4.46 million, or $3.26 per share, in Q2 2025. The loss included a $5.4 million valuation loss on the June 2026 PIPE and a $2.8 million unrealized loss on Above Food stock.
-
Zola Sales Inflect in July
July monthly Zola sales topped $740,000, more than half of the entire Q2 revenue of $1.44 million, and exceeded $1 million through the first week of August. Management attributed the inflection to resolving low inventory and shipping delays.
-
Cash Position and Burn Improve
The company ended Q2 with $4.2 million in cash after the $4 million private placement. Net cash used in operating activities was only $319,000 in Q2, and SG&A declined by $1.0 million year-over-year to an all-time low.
-
New Product Launches Planned
Arcadia will launch a 1-liter espresso in Q4 2026 with pre-launch commitments from its two largest customers, and plans to launch three additional new products in the first half of 2027.
Analysis · RKDA · Energy & Transportation
The Q2 net loss widened to $6.27 million from $4.46 million a year ago, driven by a $5.4 million valuation loss on the June PIPE and a $2.8 million unrealized loss on Above Food stock. However, the company ended the quarter with $4.2 million in cash after the $4 million private placement, and operating cash burn was only $319,000. Management highlighted that Zola sales reached an inflection point: July sales exceeded $740,000, more than half of the entire second quarter's revenue, and surpassed $1 million through the first week of August. The company also announced a Q4 2026 launch of a 1-liter espresso with pre-launch commitments from its two largest customers, plus three additional products planned for the first half of 2027. This is a mixed picture: severe accounting losses and going-concern risk persist, but the underlying operating business is showing signs of stabilization and growth.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1528 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKDA was trading at $0.57 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.50 to $6.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.